VIDEO: Toolbox 'growing' for PBC treatment in recent years

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I think it's always an interesting question when you think about pipeline, because actually, there's been so much advances in the opportunities for treating PBC since 2016 when obeticholic acid got conditionally approved and in 2024, two PPAR agonists were approved for the treatment of PBC. And in 2025, the readout of phase three clinical trial of a specific itch therapy for PBC is also expected. What that means is that our toolbox is already greater and growing, and then there are still other compounds in phase two development looking at other ways to use PPAR agonism, other IBAT inhibitors for the treatment of pruritus. And industry continues to refine potential ways to target PBC in a more rational and specific way, all with the goal of slowing down disease progression and improving quality of life.